SG47101A1 - Crystalline amifostine compositions and methods for the preparation and use of same - Google Patents
Crystalline amifostine compositions and methods for the preparation and use of sameInfo
- Publication number
- SG47101A1 SG47101A1 SG1996007320A SG1996007320A SG47101A1 SG 47101 A1 SG47101 A1 SG 47101A1 SG 1996007320 A SG1996007320 A SG 1996007320A SG 1996007320 A SG1996007320 A SG 1996007320A SG 47101 A1 SG47101 A1 SG 47101A1
- Authority
- SG
- Singapore
- Prior art keywords
- present
- compositions
- crystalline
- preparation
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001097 amifostine Drugs 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Insulating Materials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Sub-Exchange Stations And Push- Button Telephones (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92292992A | 1992-07-31 | 1992-07-31 | |
US08/099,298 US5424471A (en) | 1992-07-31 | 1993-07-29 | Crystalline amifostine compositions and methods of the preparation and use of same |
Publications (1)
Publication Number | Publication Date |
---|---|
SG47101A1 true SG47101A1 (en) | 1998-03-20 |
Family
ID=26795942
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG1996007320A SG47101A1 (en) | 1992-07-31 | 1993-06-30 | Crystalline amifostine compositions and methods for the preparation and use of same |
Country Status (23)
Country | Link |
---|---|
US (1) | US5591731A (zh) |
EP (1) | EP0655917B1 (zh) |
JP (1) | JP3503943B2 (zh) |
CN (2) | CN1070370C (zh) |
AT (1) | ATE261729T1 (zh) |
AU (1) | AU681858B2 (zh) |
CA (1) | CA2120133C (zh) |
CZ (1) | CZ284417B6 (zh) |
DE (1) | DE69333453T2 (zh) |
DK (1) | DK0655917T3 (zh) |
ES (1) | ES2215992T3 (zh) |
HK (1) | HK1010692A1 (zh) |
HU (1) | HU227122B1 (zh) |
IL (1) | IL106540A (zh) |
IS (1) | IS1843B (zh) |
MX (1) | MX9304627A (zh) |
NO (2) | NO309636B1 (zh) |
NZ (1) | NZ255182A (zh) |
PL (1) | PL178463B1 (zh) |
PT (1) | PT655917E (zh) |
RU (1) | RU2125880C1 (zh) |
SG (1) | SG47101A1 (zh) |
SK (1) | SK283318B6 (zh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6051563A (en) | 1997-02-12 | 2000-04-18 | U.S. Bioscience, Inc. | Methods for the administration of amifostine and related compounds |
US6573253B2 (en) | 1997-02-12 | 2003-06-03 | Medimmune Oncology Inc. | Methods for the administration of amifostine and related compounds |
US5994409A (en) * | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
US6239119B1 (en) | 1998-04-27 | 2001-05-29 | Medimmune Oncology, Inc. | Topical administration of amifostine and related compounds |
US6017922A (en) * | 1998-05-18 | 2000-01-25 | U.S. Bioscience, Inc. | Thermally stable trimetrexates and processes for producing the same |
US6407278B2 (en) * | 1998-11-16 | 2002-06-18 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and methods for the preparation and use of the same |
US6384259B1 (en) | 1998-11-16 | 2002-05-07 | Medimmune Oncology, Inc. | Stable amorphous amifostine compositions and dosage form |
DE10043170C2 (de) * | 2000-09-01 | 2002-10-24 | Klinge Co Chem Pharm Fab | Amifostin-Monohydrat und Verfahren zu seiner Herstellung |
CN1148192C (zh) * | 2000-10-19 | 2004-05-05 | 南京振中生物工程有限公司 | 细胞保护剂氨磷汀制剂及其制备方法 |
US7053072B2 (en) | 2001-05-11 | 2006-05-30 | Medimmune Oncology, Inc. | Methods for the administration of amifostine and related compounds |
EP2316468A1 (en) | 2002-02-22 | 2011-05-04 | Shire LLC | Delivery system and methods for protecting and administering dextroamphetamine |
US7629333B2 (en) * | 2002-03-29 | 2009-12-08 | Medimmune, Llc | Stable amorphous amifostine compositions and methods for the preparation and use of same |
CN1305478C (zh) * | 2004-05-12 | 2007-03-21 | 天津市资福医药科技开发有限公司 | 氨磷汀冻干制剂及其制备方法 |
CA2597982C (en) * | 2005-02-16 | 2014-07-08 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
US7767657B2 (en) | 2005-02-16 | 2010-08-03 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
WO2007047315A1 (en) * | 2005-10-20 | 2007-04-26 | Albemarle Corporation | Amifostine dihydrate crystalline composition |
US8158152B2 (en) * | 2005-11-18 | 2012-04-17 | Scidose Llc | Lyophilization process and products obtained thereby |
SI2719388T1 (sl) | 2006-02-16 | 2019-06-28 | Anacor Pharmaceuticals, Inc. | Majhne molekule, polnjene z borom, kot učinkovine proti vnetjem |
US9585849B2 (en) | 2006-04-17 | 2017-03-07 | The Burlington Hc Research Group, Inc. | Broad spectrum antiviral and methods of use |
EP2010166B1 (en) * | 2006-04-17 | 2013-11-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Organic disulfide antiretroviral agents |
WO2008060441A2 (en) * | 2006-11-09 | 2008-05-22 | Scidose Llc | Stable amifostine liquid concentrate |
MX2010009765A (es) | 2008-03-06 | 2013-07-12 | Anacor Pharmaceuticals Inc | Moleculas pequeñas que contienen boro como agentes anti-inflamatorios. |
EP2285384A4 (en) * | 2008-05-12 | 2012-04-25 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
CN101347412B (zh) * | 2008-09-02 | 2011-07-27 | 大连美罗药业股份有限公司 | 三水合氨磷汀结晶冻干制剂及其制备方法 |
CN101412732B (zh) * | 2008-09-02 | 2011-09-07 | 大连美罗药业股份有限公司 | 三水合3-氨基丙基胺乙基硫代磷酸高纯稳定晶体及其制备方法 |
EP2348863A4 (en) * | 2008-09-04 | 2012-03-07 | Anacor Pharmaceuticals Inc | BORN SMALL MOLECULES |
WO2010028005A1 (en) | 2008-09-04 | 2010-03-11 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
US9493489B2 (en) * | 2008-10-15 | 2016-11-15 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as anti-protozoal agents |
EP2378886A4 (en) * | 2008-12-17 | 2012-08-29 | Anacor Pharmaceuticals Inc | (S) -3-Aminomethyl-7- (3-hydroxypropoxy) -3H-benzo [c] [1,2] oxaborole-1-OL-POLYMORPHS |
BR112012001987A2 (pt) * | 2009-07-28 | 2015-09-01 | Anacor Pharmaceuticals Inc | Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase. |
AP4039A (en) | 2009-08-14 | 2017-02-28 | Daitao Chen | Boron-containing small molecules as antiprotozoal agents |
WO2011022337A1 (en) * | 2009-08-19 | 2011-02-24 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US20110124597A1 (en) * | 2009-09-25 | 2011-05-26 | Anacor Pharmaceuticals, Inc. | Boron containing small molecules |
WO2011049971A1 (en) | 2009-10-20 | 2011-04-28 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules as antiprotozoal agents |
US20110212918A1 (en) * | 2009-11-11 | 2011-09-01 | Anacor Pharmaceuticals, Inc. | Boron-containing small molecules |
PT2501234T (pt) * | 2009-11-20 | 2017-12-13 | Tonix Pharma Holdings Ltd | Métodos e composições para o tratamento de sintomas associados com distúrbios de stress pós-traumático utilizando ciclobenzaprina |
WO2011094450A1 (en) | 2010-01-27 | 2011-08-04 | Anacor Pharmaceuticals, Inc | Boron-containing small molecules |
AP2012006482A0 (en) | 2010-03-19 | 2012-10-31 | Anacor Pharmacueticals Inc | Boron-containing small molecules as anti-protozoalagent |
US20110319389A1 (en) | 2010-06-24 | 2011-12-29 | Tonix Pharmaceuticals, Inc. | Methods and compositions for treating fatigue associated with disordered sleep using very low dose cyclobenzaprine |
JP5952280B2 (ja) | 2010-09-07 | 2016-07-13 | アナコール ファーマシューティカルズ,インコーポレーテッド | 細菌感染治療用のベンゾオキサボロール誘導体 |
US11998516B2 (en) | 2011-03-07 | 2024-06-04 | Tonix Pharma Holdings Limited | Methods and compositions for treating depression using cyclobenzaprine |
TWI432204B (zh) * | 2011-06-03 | 2014-04-01 | Taiwan Hopax Chems Mfg Co Ltd | 對抗自由基的醫藥組合物 |
CN102286020A (zh) * | 2011-07-11 | 2011-12-21 | 大连美罗大药厂 | 一水合3-氨基丙基胺乙基硫代磷酸的制备方法 |
BR112015022095B1 (pt) | 2013-03-15 | 2021-12-07 | Tonix Pharmaceuticals, Inc | Composição farmacêutica, métodos de fabricação, composição eutética e uso de composições |
CA2915708C (en) * | 2013-06-18 | 2018-02-06 | Aminomedix Inc. | Compositions and methods for the preparation of kidney protective agents comprising amifostine and amino acids |
CN107072968B (zh) | 2014-09-18 | 2021-01-12 | 通尼克斯制药控股有限公司 | 环苯扎林盐酸盐的低共熔混合物配制剂 |
CA2963458C (en) * | 2014-10-02 | 2023-09-26 | Cytosorbents Corporation | Use of gastrointestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome |
US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
CN111447971A (zh) | 2017-12-11 | 2020-07-24 | 通尼克斯制药控股有限公司 | 用于痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 |
CN110616463B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备有机半导体分子单晶或无定型物的方法 |
CN110607551B (zh) * | 2018-10-30 | 2024-02-20 | 中国科学院化学研究所 | 一种制备食品添加剂单晶或无定型物的方法 |
WO2020088480A1 (zh) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | 一种利用溶液冻结制备单晶或无定型物的方法 |
CN118267895A (zh) * | 2018-10-30 | 2024-07-02 | 中国科学院化学研究所 | 一种制备药物或药物中间体无定型物的方法 |
CN110606868A (zh) * | 2018-10-30 | 2019-12-24 | 中国科学院化学研究所 | 一种制备多肽或蛋白质单晶或无定型物的方法 |
WO2020088479A1 (zh) * | 2018-10-30 | 2020-05-07 | 中国科学院化学研究所 | 一种利用水溶液制备单晶或无定型物的方法 |
CN110735176B (zh) * | 2018-10-30 | 2024-03-22 | 中国科学院化学研究所 | 一种制备配位化合物单晶或无定型物的方法 |
EP3824880A1 (en) * | 2019-11-25 | 2021-05-26 | Clevexel Pharma | Freeze-dried powder containing 2-[(3-aminopropyl)amino]ethanethiol and its use for preparing a thermogel |
KR20240041506A (ko) * | 2022-09-23 | 2024-04-01 | 주식회사 경보제약 | 아비박탐 나트륨 염의 안정한 일수화물 형태 및 그의 제조 방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3892824A (en) * | 1968-12-16 | 1975-07-01 | Southern Res Inst | S-{107 -({107 -aminoalkylamino)alkyl dihydrogen phosphorothioates |
JPS6041676B2 (ja) * | 1977-09-21 | 1985-09-18 | 山之内製薬株式会社 | S−2−(3−アミノプロピルアミノ)エチルジハイドロジエンホスホロチオエ−ト1水和結晶の新規製法 |
US4424216A (en) * | 1979-07-31 | 1984-01-03 | The Rockefeller University | Method for the reduction of mucin viscosity |
ATE82505T1 (de) * | 1984-08-08 | 1992-12-15 | Survival Technology | Absorptionsverbesserer. |
AU638251B2 (en) * | 1989-05-24 | 1993-06-24 | U.S. Bioscience, Inc. | Method for protection from azt side effects and toxicity |
-
1993
- 1993-06-30 SG SG1996007320A patent/SG47101A1/en unknown
- 1993-07-30 IL IL10654093A patent/IL106540A/xx not_active IP Right Cessation
- 1993-07-30 PL PL93307298A patent/PL178463B1/pl unknown
- 1993-07-30 DE DE69333453T patent/DE69333453T2/de not_active Expired - Lifetime
- 1993-07-30 IS IS4060A patent/IS1843B/is unknown
- 1993-07-30 AT AT93918552T patent/ATE261729T1/de active
- 1993-07-30 DK DK93918552T patent/DK0655917T3/da active
- 1993-07-30 CA CA002120133A patent/CA2120133C/en not_active Expired - Lifetime
- 1993-07-30 PT PT93918552T patent/PT655917E/pt unknown
- 1993-07-30 MX MX9304627A patent/MX9304627A/es unknown
- 1993-07-30 AU AU47966/93A patent/AU681858B2/en not_active Expired
- 1993-07-30 JP JP50547994A patent/JP3503943B2/ja not_active Expired - Lifetime
- 1993-07-30 SK SK113-95A patent/SK283318B6/sk not_active IP Right Cessation
- 1993-07-30 NZ NZ255182A patent/NZ255182A/en not_active IP Right Cessation
- 1993-07-30 ES ES93918552T patent/ES2215992T3/es not_active Expired - Lifetime
- 1993-07-30 EP EP93918552A patent/EP0655917B1/en not_active Expired - Lifetime
- 1993-07-30 CZ CZ95230A patent/CZ284417B6/cs not_active IP Right Cessation
- 1993-07-30 HU HU9500277A patent/HU227122B1/hu unknown
- 1993-07-30 RU RU95105441A patent/RU2125880C1/ru active
- 1993-07-31 CN CN93117436A patent/CN1070370C/zh not_active Expired - Lifetime
-
1995
- 1995-01-30 NO NO950343A patent/NO309636B1/no not_active IP Right Cessation
- 1995-02-16 US US08/389,386 patent/US5591731A/en not_active Expired - Lifetime
-
1998
- 1998-10-29 HK HK98111596A patent/HK1010692A1/xx not_active IP Right Cessation
-
2000
- 2000-11-15 NO NO20005775A patent/NO315691B1/no not_active IP Right Cessation
- 2000-12-01 CN CNB00128097XA patent/CN1146428C/zh not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG47101A1 (en) | Crystalline amifostine compositions and methods for the preparation and use of same | |
MY110631A (en) | Crystalline amifostine compositions and methods for the preparation and use of same. | |
CA2063106A1 (en) | Ciclosporin form for pulmonary administration | |
EP0840599A4 (en) | DRUGS WITH CONJUGATED ESTROGENES AND METHOD FOR THEIR USE | |
FI935847A (fi) | L-DOPA-esterikoostumukset | |
WO2001005355A3 (en) | Formulations for il-11 | |
IL98881A0 (en) | Esters of heterocyclic compounds,their preparation and pharmaceutical compositions containing them | |
TW427906B (en) | Antifungal compositions | |
ZA979647B (en) | Heterocyclic compounds, compositions and uses. | |
HU895241D0 (en) | Process for the preparation of substituted 1,3,5-triazin-trione derivatives and pharmaceutical compositions containing said compounds as active ingredient | |
UA74388C2 (uk) | Фармацевтичні композиції тизоксаніду і нітазоксаніду | |
AU711128C (en) | Anti-helicobacter pylori compositions containing 1-methylcarbapenem derivatives as the active ingredient | |
ZA979650B (en) | Heterocyclic compounds, compositions and uses. | |
ZA979645B (en) | Heterocyclic compounds, compositions and uses. | |
DE60031557D1 (de) | Steroide, ihre herstellung , pharmazeutische zusammensetzungen mit ihnen und verwendungen dieser verbindungen | |
EP0382635A3 (fr) | Utilisation de dérivés d'alkyl-5 pyridazine comme médicaments actifs sur le système cholinergique | |
HUT56716A (en) | Process for producing pharmaceutical compositions suitable for preventing and treating autoimmune illnesses and skin diseases caused by heat and light radiation | |
BG106093A (en) | 14beta-h-sterols, pharmaceutical compositions comprising them and the use of these derivatives for the preparation of meiosis regulating medicaments | |
GEP20002241B (en) | Polymorphs and Hydrated Forms of Lesopitron Dichlorohydrate, Methods for Its Preparation and Pharmaceutical Compositions Containing Same | |
ITMI912324A0 (it) | Derivati dall'acido beta-idrossibutirrico, procedimento per la loro preparazione e relative composizioni farmaceutiche | |
IT1248525B (it) | Derivati dell'eseridina utili per il trattamento delle malattie associate a disordini colinergici, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono. | |
JO1679B1 (en) | A new, therapeutically active compound and method for preparing it |